JP2014521658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521658A5 JP2014521658A5 JP2014523092A JP2014523092A JP2014521658A5 JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5 JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014523092 A JP2014523092 A JP 2014523092A JP 2014521658 A5 JP2014521658 A5 JP 2014521658A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amount
- laquinimod
- day
- glatiramer acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512808P | 2011-07-28 | 2011-07-28 | |
| US61/512,808 | 2011-07-28 | ||
| PCT/US2012/048684 WO2013016684A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230818A Division JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521658A JP2014521658A (ja) | 2014-08-28 |
| JP2014521658A5 true JP2014521658A5 (OSRAM) | 2015-09-17 |
Family
ID=47597714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523092A Withdrawn JP2014521658A (ja) | 2011-07-28 | 2012-07-27 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
| JP2016230818A Withdrawn JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016230818A Withdrawn JP2017081930A (ja) | 2011-07-28 | 2016-11-29 | ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130029916A1 (OSRAM) |
| EP (1) | EP2736335A4 (OSRAM) |
| JP (2) | JP2014521658A (OSRAM) |
| KR (1) | KR20140054166A (OSRAM) |
| CN (2) | CN105944081A (OSRAM) |
| AU (2) | AU2012286699A1 (OSRAM) |
| BR (1) | BR112014002095A2 (OSRAM) |
| CA (1) | CA2843433A1 (OSRAM) |
| CL (2) | CL2014000209A1 (OSRAM) |
| EA (1) | EA201490377A1 (OSRAM) |
| HK (2) | HK1198279A1 (OSRAM) |
| IL (1) | IL251397A0 (OSRAM) |
| IN (1) | IN2014MN00333A (OSRAM) |
| MX (1) | MX2014001050A (OSRAM) |
| PE (1) | PE20142319A1 (OSRAM) |
| SG (1) | SG10201606191PA (OSRAM) |
| UY (1) | UY34358A (OSRAM) |
| WO (1) | WO2013016684A1 (OSRAM) |
| ZA (1) | ZA201401371B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| SG183513A1 (en) | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| KR20160129093A (ko) * | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
| JP2015505564A (ja) | 2012-02-03 | 2015-02-23 | テバ ファーマシューティカル インダストリーズ リミティド | 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| US9233927B2 (en) | 2013-03-14 | 2016-01-12 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EP3043647A4 (en) * | 2013-09-12 | 2017-05-10 | Teva Pharmaceutical Industries Ltd. | Gene expression biomarkers of laquinimod responsiveness |
| CN105848653A (zh) * | 2013-09-27 | 2016-08-10 | 梯瓦制药工业有限公司 | 用于治疗多发性硬化症的拉喹莫德联合治疗 |
| CA2930113A1 (en) * | 2013-11-15 | 2015-05-21 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| US20150361757A1 (en) * | 2014-06-17 | 2015-12-17 | Baker Hughes Incoporated | Borehole shut-in system with pressure interrogation for non-penetrated borehole barriers |
| WO2016044103A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceutical Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| US20170028013A1 (en) * | 2015-07-30 | 2017-02-02 | Teva Pharmaceutical Industries, Ltd. | Combination formulation of laquinimod and glatiramer acetate with amino acids |
| US20240252461A1 (en) * | 2018-04-13 | 2024-08-01 | Mordechai Chevion | Compositions and methods for treatment of demyelination |
| MX2022006439A (es) | 2019-12-19 | 2022-07-19 | Active Biotech Ab | Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva. |
| KR102350943B1 (ko) * | 2021-07-12 | 2022-01-14 | 주식회사 바움디자인시스템즈 | 집적 회로에 대한 소비 전력을 예측하는 방법 및 이를 수행하는 소비 전력 예측 시스템 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US7989473B2 (en) * | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| JP2012502038A (ja) * | 2008-09-03 | 2012-01-26 | テバ ファーマシューティカル インダストリーズ リミティド | 免疫機能の２−オキソ−１，２−ジヒドロ−キノリンモジュレーター |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| EP2376456A2 (en) * | 2008-12-17 | 2011-10-19 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| DK2442651T3 (en) * | 2009-06-19 | 2015-09-21 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| WO2011056532A2 (en) * | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
-
2012
- 2012-07-27 IN IN333MUN2014 patent/IN2014MN00333A/en unknown
- 2012-07-27 PE PE2014000132A patent/PE20142319A1/es not_active Application Discontinuation
- 2012-07-27 AU AU2012286699A patent/AU2012286699A1/en not_active Abandoned
- 2012-07-27 MX MX2014001050A patent/MX2014001050A/es unknown
- 2012-07-27 CA CA2843433A patent/CA2843433A1/en not_active Abandoned
- 2012-07-27 SG SG10201606191PA patent/SG10201606191PA/en unknown
- 2012-07-27 CN CN201610302142.2A patent/CN105944081A/zh active Pending
- 2012-07-27 BR BR112014002095A patent/BR112014002095A2/pt not_active IP Right Cessation
- 2012-07-27 HK HK14111812.7A patent/HK1198279A1/xx unknown
- 2012-07-27 CN CN201280043755.9A patent/CN103781354A/zh active Pending
- 2012-07-27 KR KR1020147005638A patent/KR20140054166A/ko not_active Withdrawn
- 2012-07-27 EP EP12817089.1A patent/EP2736335A4/en not_active Withdrawn
- 2012-07-27 EA EA201490377A patent/EA201490377A1/ru unknown
- 2012-07-27 US US13/560,851 patent/US20130029916A1/en not_active Abandoned
- 2012-07-27 JP JP2014523092A patent/JP2014521658A/ja not_active Withdrawn
- 2012-07-27 WO PCT/US2012/048684 patent/WO2013016684A1/en not_active Ceased
- 2012-10-01 UY UY0001034358A patent/UY34358A/es not_active Application Discontinuation
-
2014
- 2014-01-28 CL CL2014000209A patent/CL2014000209A1/es unknown
- 2014-02-21 ZA ZA2014/01371A patent/ZA201401371B/en unknown
-
2015
- 2015-07-16 US US14/801,595 patent/US20160038532A1/en not_active Abandoned
-
2016
- 2016-05-06 US US15/148,074 patent/US20160361352A1/en not_active Abandoned
- 2016-07-11 AU AU2016204777A patent/AU2016204777A1/en not_active Abandoned
- 2016-08-24 CL CL2016002132A patent/CL2016002132A1/es unknown
- 2016-11-29 JP JP2016230818A patent/JP2017081930A/ja not_active Withdrawn
- 2016-12-22 HK HK16114575.6A patent/HK1226940A1/zh unknown
-
2017
- 2017-03-27 IL IL251397A patent/IL251397A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521658A5 (OSRAM) | ||
| US11648232B2 (en) | Methods and compositions for treating excessive sleepiness | |
| JP2014530821A5 (OSRAM) | ||
| JP2010518122A5 (OSRAM) | ||
| JP2013544887A5 (OSRAM) | ||
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| JP2014515373A5 (OSRAM) | ||
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| CN103732062A (zh) | 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 | |
| JP2015512406A5 (OSRAM) | ||
| CA2294589A1 (en) | Composition for controlling mood disorders in healthy individuals | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2017510607A5 (OSRAM) | ||
| JP2010513250A5 (OSRAM) | ||
| JP2015522077A5 (OSRAM) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| TW202333733A (zh) | 一種(6S)-N-[4-({(2S,5R)-5-[(R)-羥基(苯基)甲基]吡咯啶-2-基}甲基)苯基]-4-側氧-4,6,7,8-四氫吡咯并[1,2-a]嘧啶-6-甲醯胺用於夜間頻尿治療劑之醫藥製造之用途 | |
| CA2859004A1 (en) | Methods and compositions for administration of oxybutynin | |
| CN100518775C (zh) | 一种治疗咳喘的药物组合物及其制剂 | |
| JP2012502105A5 (OSRAM) | ||
| JP4745661B2 (ja) | 統合失調症治療剤 | |
| JP5299949B2 (ja) | シロスタゾールの統合失調症治療剤 | |
| JP2015524460A5 (OSRAM) | ||
| JP2016533323A5 (OSRAM) | ||
| WO2016041438A1 (zh) | 一种柚皮苷与盐酸非索非那丁药物组合物及其制剂 |